The effect of fluconazole and amphotericin B on macrophage functions by Glažar, Irena et al.









Department of Oral Medicine, Dental Clinic, University Hospital Rijeka, Croatia
2
Department of Microbiology, University Hospital Rijeka, Croatia
Primljen/Received 31. 08. 2015. god. Prihva}en/Accepted 24. 10. 2015. god.
Abstract: Background: Different antimicrobial
drugs inhibit functions of the microbial cells but, un-
fortunately, some of these drugs can also affect the host
cells, including macrophages. Since these cells repre-
sent the baseline defense against microbial agents, it is
important that they are fully activated.
Materials and Methods: In the present study we
investigated the effect of amphotericin B and flucona-
zole on the functions of peritoneal macrophages from
Balb/c mice treated with these antimycotics. For each
antimycotic the therapeutic dose used in clinical prac-
tice (calculated on the mouse body weight) and
two-fold higher doses were administered intraperito-
neally once a day for three consecutive days. The con-
trol group was treated with saline in the same way. Fo-
ur different tests, candidacidal assay, nitroblue tetrazo-
lium test, adherence capability and phagocytic capabil-
ity, were used to determine macrophage functions.
Results: Our results confirmed positive effect of
high dose amphotericin B on phagocytic capability
(31.00 ± 4.46%), metabolic changes (27.93 ± 6.63%)
and adherence capacity (59.24 ± 8.67%). Lower doses
of drug amphotericin B (2 mg/kg) significantly increa-
sed the adherence index of macrophages (71.99 ±
5.55%) and intensity of the NBT intracellular reduc-
tion (30.20 ± 3.83%). Maximum dose of fluconazole
expressed significantly higher phagocytic index (30.77
± 2.17%), metabolic changes (24.00 ± 4.07%) and can-
didacidal activities (27.73 ± 6.73%), while lower doses
of fluconazole (15 mg/kg) significantly increased the
adherence index of macrophages (75.58 ± 5.47%) as
well as the phagocytic index (29.23 ± 2.40%). Other
results were similar as in control group.
Conclusion: Positive immunomodulatory effects
of fluconazole and amphotericin B may be clinically
relevant especially in compromised patients who are
predisposed to opportunistic fungal infections and re-
quire a long-term antimycotic therapy. Synergistic ac-
tion of macrophages and antimycotics can influence
the course of disorders related to immune suppression.
Key words: Amphotericin B, fluconazole, mac-
rophage functions.
INTRODUCTION
Fungal infections pose a growing medical prob-
lem because of the markedly increased numbers of im-
munologically compromised patients due to human
immunodeficiency virus, cancer chemotherapy, bone
marrow transplantation or other debilitating conditions
(1, 2). These infections are commonly associated with
significant morbidity and mortality. Many of these in-
fections are caused by, in normal conditions, harmless
fungi. The most common infection associated with this
group of patients is candidiasis (3–5). Resistance to
fungal infections is based on cell-mediated immunity.
Macrophages play a key role in the host immune sys-
tem. They act as a barrier against microbial invasion
and dissemination. Their ability to be mobilized into
infectious sites from bone marrow and blood, as well as
their competence for phagocytosis and killing of mic-
roorganisms is often decisive in determining the outco-
me of infection (1, 6–8). Once activated, they act di-
rectly by destroying bacteria, parasites, viruses, fungi
and tumor cells with reactive oxidants and hydrolytic
enzymes, or indirectly by releasing specific mediators
such as interleukin-1, tumor necrosis factor-alpha and
others which can regulate other cells’ activities. They
are also responsible for processing the antigens and
presenting the digested peptides to lymphocytes, while
playing the leading role in damage repair (9–11). How-
ever, chemotherapeutic agents, corticosteroids, and ra-
diation, disrupt these defense mechanisms. If patients
are to survive infections associated with neutropenia
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and other compromises in host defense due to use of
these therapies, it is important to reverse or at least les-
sen immunosuppresion in this patients (2, 4).
Fungal infections are treated with antifungal
drugs. Antifungal agents which are available for treat-
ment of these infections are the polyenes, the azoles
and the echinocandins (12–14). Polyene antifungal
drug amphotericin B is a standard therapy for invasive
Candida infections, but high frequency of renal toxic-
ity limits its use. Recently, newer lipid formulations of
amphotericin B with less adverse effects and activities
similar to that of standard amphotericin B have become
available (15). The triazole fluconazole is a leading
drug to prevent and to treat candidal infections. This
drug displays predictable pharmacokinetics and an ex-
cellent tolerance profile in all groups of patients
(12–14, 16).
Different antimicrobial drugs inhibit functions of
the microbial cells but, unfortunately, some of these
drugs can also affect the host cells, including macrop-
hages. Since these cells represent the baseline of defen-
se against microbial agents, it is important that these
cells are fully activated (14, 15).
The aim of this study was to investigate the effect of
amphotericin B and fluconazole on macrophage functi-
ons (adherence, phagocytosis, intracellular killing and di-
gestion of the drug) on experimental mouse model.
MATERIALS AND METHODS
Animals. Female BALB/c mice, 9 weeks old (ob-
tained from the Medical Faculty, University of Rijeka)
were used in this study. They were randomly divided in
five groups each containing five animal. The animals
were kept in plastic cages and were given standard lab-
oratory rodent food and water ad libidum. The Ethical
Committee of the Medical Faculty University of Rije-
ka approved the study and all procedures using mice.
Antimycotics. Two antifungal drugs Amphoteri-
cin-B (Amphotericin-B, Bristol-Myers Squibb, Woer-
den, The Netherlands) and fluconazole (Diflucan, Pfi-
zer, Ambroise, France) were tested.
For each antimycotic, the therapeutic dose used in
clinical practice (calculated on the mouse body weight)
and twofold higher dose were administrated intraperi-
toneally once a day, for three consecutive days. Stan-
dard preparation of amphotericin B was given in doses
of 2 mg/kg/day and 4 mg/kg/day while fluconazole
was administrated in doses of 15 and 30 mg/kg/day.
Control group was treated with saline (0,85% NaCl) in
the same way.
Peritoneal macrophages. 24 h after receiving the
last dose of the antimycotic, the animals were sacrifi-
ced by cervical dislocation. Peritoneal macrophages
were obtained after the peritoneal cavity was washed
with 4 ml of RPMI medium (Institute of Immunology,
Zagreb, Croatia). The injected medium containing pe-
ritoneal cells was slowly aspirated. Quantitative analy-
sis of the cell suspension was performed immediately
after collection in a Neubauer chamber.
Macrophage adherence assay. Two plastic test tu-
bes (16 x 160 mm) were filled with 0.2 ml of the same
cell suspension. The tubes were incubated for 2 hours in
a horizontal position at 37 °C in a humidified atmosphe-
re. After gentle removal, the number of nonadherent
macrophages was counted in a Neubauer chamber. The
results were expressed as the adherence index (AI).
Phagocytic assay. Two plastic rings, 2 mm high and
16 mm in diameter, were stuck with paraffin onto micro-
scopic slides. The wells were filled with the cell suspen-
sion containing peritoneal macrophages in RPMI medi-
um and heat killed Candida albicans. The wells were
covered with cover slips and incubated at 37 °C for 30
minutes in a humid atmosphere. After incubation the co-
ver slips were removed and the liquid was decanted. The
plastic rings were removed and the slides were dried,
stained with Wright’s stain and examined with immer-
sion. The total number of macrophages and the percent-
age of ingested Candida albicans were counted. More
than 100 cells per each well were counted. The results
were expressed as phagocytic index (PI).
Candidacidal assay. Plastic tubes were filled with
0.1 ml of cell suspension and 0.005 ml suspension of
viable Candida albicans. The tubes were then incuba-
ted at 37 °C for one hour in a humid atmosphere. After
incubation, the suspension was treated with cold distil-
led water for 15 minutes to cause cells lysis. Light mic-
roscopic examination showed blue killed Candida
while the alive ones remained were colorless. Free
Candida albicans was colored with Tripan blue. More
than 300 Candida were counted and the results were
expressed as percentage of killed Candida albicans at
100 microorganisms.
Nitroblue tetrazolium (NBT)-dye assay. NBT-as-
say expresses metabolic changes in the macrophages
after phagocytosis foreign particles. Metabolic chan-
ges include reduction of the colorless NBT in the cyto-
plasm of macrophages in black color formasan. Plastic
tubes were filled with 200 l of the cell suspension and
200 l of the nitroblue tetrazolium. The tubes were
then incubated at 35E C for 15 minutes in a humid at-
mosphere and for 15 minutes at room temperature. The
suspension was then placed on microscopic slides and
dried. Immediately after, dried slides were stained with
Wright’s stain and examined with immersion. The total
number of macrophages and the percentage of forma-
san positive cells with blue or black inclusions were
determined. More than 100 cells per slides were coun-
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ted. Results were expressed as percentage of NBT pos-
itive cells.
Comparison between groups was performed by
Student t-test. Results are expressed as mean and stan-
dard deviation. The level of significance was set at 0.05.
All animal experiments were carried out in accor-
dance with Policies and Guidelines for the Care and
Use Laboratory Animals. All effort was made to mini-
mize animal suffering.
RESULTS
The effect of fluconazole
on macrophage functions
Our results showed that lower dose of fluconazole
(15 mg/kg) significantly increased the adherence index
of macrophages (75.58 ± 5.47%) as well as the pha-
gocytic index (29.23 ± 2.40%), but did not demonstrate
any major alteration in C. albicans killing assay and
NBT intracellular reduction.
Macrophages treated with maximum dose (30
mg/kg) of fluconazole had significantly higher pha-
gocytic index (30.77 ± 2.17%), metabolic changes
(24.00 ± 4.07%) and candidacidal activities (27.73 ±
6.73%) comparing to control group (p  0.05).
The effect of amphotericin B
on macrophage functions
Lower doses of drug amphotericin B (2 mg/kg)
significantly increased the adherence index of macrop-
hages (71.99 ± 5.55%) and intensity of the NBT intra-
cellular reduction (30.20 ± 3.83%), while other results
were similar to the control group.
Treatment of macrophages with higher dose of
amphotericin B (4 mg/kg) showed that phagocytic ca-
pability (31.00 ± 4.46%), metabolic changes (27.93 ±
6.63%) and adherence capacity (59.24 ± 8.67%) were
increased significantly.
Results are summarized in Table 1.
DISCUSION
The host response to fungal infections requires
co-actions of immune system and antifungal drugs to
effectively clear the microorganisms. Antifungal drugs
may have broad immunomodulatory properties. Cyto-
kines, effector cells, and antifungals appear to work
synergistically to oppose fungal growth. Positive im-
munomodulatory effects of antifungal drugs may be
clinically relevant, especially in compromised patients
who are predisposed to opportunistic fungal infections
and require a long-term antimycotic therapy (17).
In this study, the most commonly used antifungal
drugs were studied for their impact on different mac-
rophage functions. Several studies examined the influ-
ence of fluconazole on macrophage activity against
Candida. It appears that the presence of macrophages
provides synergistic activity with fluconazole against
Candida isolates (14). Garcha presented the data that
indicate that the combination of two fungistatic agents,
fluconazole and macrophages, can synergize for signi-
ficant anticandidal activity, especially against flucona-
zole-susceptible isolates (18). In contrast, investigation
presented by Yamaguchi et al. suggested that fluconazo-
le had no immunological effect (19). Results of our in-
vestigation confirmed synergic activity of as a stimulant
on phagocytosis, oxidative burst and microbicidal activ-
ity using both fluconazole and macrophages in immune
response. We found that fluconazole acted maximum
dose and lower dose of fluconazole, although better re-
sults were obtained with maximum dose. Fidan and his
co-workers concluded in their research that fluconazole
has an immunomodulatory effect connected with the
presence of different cytokines (17).
It is well known that Amphotericin B has an im-
munostimulatory effect to macrophages and enhances
their function (17, 19). It also has a stimulatory effect
on macrophages to produce cytokine tumor necrosis
factor alpha (TNF-) which may be responsible for the
immunomodulatory effects of Amphotericin B (20).









Control 62.21 ± 14.26 22.95 ± 3.55 20.93 ± 1.71 14.10 ± 623
Fluconazole (15 mg/kg/day) 75.58 ± 5.47* 29.23 ± 2.40* 19.20 ± 3.52 11.40 ± 4.40
Fluconazole (30 mg/kg/day) 68.84 ± 8.68 30.77 ± 2.17* 24.00 ± 4.07* 27.73 ± 6.73*
AmphotericinB (2 mg/kg/day) 71.99 ± 5.55* 22.67 ± 3.32 30.20 ± 3.83* 11.13 ± 4.51
AmphotericinB (4 mg/kg/day) 59.24 ± 8.67* 31.00 ± 4.46* 27.93 ± 6.63* 12.60 ± 4.65
Values are expressed as mean ± SD from each group. Student t-test was used to compare data among the groups.
* Significant increased functions comparing to control group at level p < 0.05.
Table 1. Adherence index, Phagocytic index, NBT-dye assay and Candidacidal assay
for amphotericin B and fluconazole
We confirmed that both doses of amphotericin B had
effect on macrophages, increasing significantly their
phagocytic ability and oxidative burst. Our results are
also in correlation with the results obtained by Yama-
guchi who concluded that amphotericin B has a profo-
und effect on macrophages in vitro and in vivo, and
that this action is mediated by cytokines (19).
Antifungals used to treat infections, especially in
immunocompromised patients, could have a potent an-
timicrobial effect to fungi and positive impact on host
defense mechanisms such as macrophage functions.
CONCLUSION
It is preferable that drugs used have a slightly sti-
mulatory, rather than an immunosuppressive effect on
the cells of the immune system. Since some drugs can
suppress macrophage functions, it would be appropria-
te to determine susceptibility of microorganisms to a
certain drug since even minor immunosuppressive ef-
fect can additionally complicate the course of the dise-
ase. Recent investigation suggested that macrophage
functions are connected with activation of different
cytokines but further studies should be carried out in
order to understand better the mechanism by which tar-
get host cells react in response to immunomodulators.
Abbreviations:
AI — adherence index
NBT assay — Nitroblue tetrazolium dye assay
TNF- — tumor necrosis factor alpha
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Uvod: Razli~iti antimikrobni lekovi inhibiraju
funkcije mikroorganizama, na`alost deluju i na }elije
doma}ina, uklju~uju}i i makrofage. Obzirom da su ma-
krofazi bazna linija odbrane organizma, potrebno je da
budu u potpunosti aktivirani.
Materijali i metode: U istra`ivaanju ispitivan je
u~inak flukonazola i amfotericina B na funkcije perito-
nealinih makrofaga Balb/c mi{eva. Za svaki antimi-
krobni lek kori{}ena je terapeutska doza i dvostruko
ve}a doza. Mi{evi su tretirani uzastopno tri dana. Kon-
trolna grupa mi{eva tretirana je s fiziolo{kim rastvo-
rom identi~nim postupkom. Da bi se odredila funkicija
makrofaga kori{}ena su ~etiri testa: kandidacidni test,
nitroblutetrazolijski test, sposobnost adherencije i fa-
gocitna sposobnost.
Rezultati: rezultati su potvrdili pozitivan u~inak
amfotericina B na fagocitozu (31.00 ± 4.46%), meta-
boli~ke promene (27.93 ± 6.63%) i sposobnost adhe-
rencije (59.24 ± 8.67%). Ni`a doza amfotericina B (2
mg/kg) zna~ajno pove}ava indeks adherencije makro-
faga (71.99 ± 5.55%) i metaboli~ke funkcije (30.20 ±
3.83%). Vi{a doza flukonazola zna~ajno pove}ava fa-
gocitni indeks (30.77 ± 2.17%), metaboli~ke aktivnosti
(24.00 ± 4.07%) i kandidacidne aktivnosti (27.73 ±
6.73%), dok ni`a doza flukonazola (15 mg/kg) zna~aj-
no pove}ava indeks adherencije (75.58 ± 5.47%) i fa-
gocotni indeks (29.23 ± 2.40%). Rezultati su sli~nii u
kontrolnoj grupi.
Zaklju~ak: Pozitivan imunomodulatorni u~inak
flukonazola i amfotericina B mo`e biti klini~ki zna~a-
jan kod imunolo{ki kompromitovanih bolesnika kod
kojih postoji predispozicija razvoja oportunisti~kih
gljivi~nih infekcija. Sinergisti~an u~inak makrofaga i
antimikotika mo`e uticati na razvoj i tok bolesti.
Klju~ne re~i: Amfotericin B, fluconazol, makro-
fagne funkcije.
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